CurrentBlue Cross Blue Shield - MassachusettsPolicy 577

DXA body composition studies

This policy governs coverage for dual-energy x-ray absorptiometry (DXA) body composition studies for Blue Cross Blue Shield - Massachusetts members across commercial and Medicare products, including inpatient and outpatient rules.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyDXA body composition studies

Policy CodePolicy 577

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization for inpatient DXA procedures; outpatient DXA body composition studies are not covered.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalCoverage stance

Not coveredOutpatient coverage

Precert requiredInpatient auth

No specific codeCPT coding

Policy 577Internal ID

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Main policy

Covered when ALL of the following are met:

Policy coverage stance: Dual x-ray absorptiometry (DXA) body composition studies are considered INVESTIGATIONAL.

Applies to commercial and Medicare products as described.

For outpatient settings, DXA body composition studies are not a covered service for the listed products: Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM.

The cited reference entries do not specify any explicit policy exclusions beyond those enumerated for outpatient services; no additional exclusion language is provided in the referenced material.

Dual-energy x-ray absorptiometry (DXA) body composition studies are designated INVESTIGATIONAL and considered investigational for all diagnoses.

There are no statements in the cited sections that classify DXA body composition studies as "not medically necessary."

Covered Indications

Clinical contexts where DXA may be used

Clinical contexts in which DXA body composition assessment has been described (policy considers these potential uses; DXA body composition is investigational):

Clinical situations discussed: Potential clinical uses described include evaluation of undernourished patients and those with disease-related wasting (eg, anorexia nervosa, cachexia), monitoring after certain treatments (eg, antiretroviral therapy, bariatric surgery), assessment of visceral versus total fat for cardiometabolic risk, assessment of growth- and age-related changes (eg, infancy/childhood growth, sarcopenia in aging), and evaluation when body mass index is discordant with fat mass (eg, body-building, edema).

These are described as potential uses but the policy states DXA body composition studies are investigational and not covered for outpatient settings as noted elsewhere.

References: clinical contexts (no modality-specific coverage indications)

References in this policy describe a range of clinical contexts where body composition assessment (including DXA) has been applied; the citations do not establish modality-specific coverage indications in this policy:

Reference summary: Cited literature covers applications of body composition assessment and DXA in areas including sarcopenia, obesity and visceral adiposity, cancer survivorship and lymphedema, liver disease and cirrhosis, pediatric growth and malnutrition, muscular dystrophy, and method-comparison studies versus other modalities.

See reference list for individual citations.

Provider Actions & Billing Guidance

Prior Authorization

Prior Authorization Required for Inpatient Procedures

For services described in this policy, precertification/preauthorization IS REQUIRED for all products when the procedure is performed inpatient. Providers must obtain authorization prior to inpatient admission to avoid denial of payment.

Applies to all product lines when performed inpatient.
Single-line prior authorization required for inpatient DXA body composition studies.

Note

Outpatient Noncoverage — All Products

Dual-energy X-ray absorptiometry (DXA) body composition studies are not covered when performed outpatient across Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM products. Restate this outpatient noncoverage to ensure provider awareness.

Commercial Managed Care (HMO and POS) — Outpatient: Not a covered service.
Commercial PPO and Indemnity — Outpatient: Not a covered service.
Medicare HMO Blue SM — Outpatient: Not a covered service.
Medicare PPO Blue SM — Outpatient: Not a covered service.

Denial Risk

Investigational / Denial Risk for DXA Body Composition Studies

DXA body composition studies for body composition (e.g., whole-body or regional body composition) are considered investigational. Claims for DXA body composition studies may be denied on the basis that the service is investigational.

Investigator/denial risk: DXA body composition studies considered investigational and may be denied.

Billing Rule

Billing and Coding Guidance

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable. Inclusion or exclusion of specific codes in policy materials does not guarantee coverage or reimbursement—verify member contract benefits at time of service.

Report services with current CPT/HCPCS/CPT-4 revenue and ICD-10 diagnosis codes and applicable modifiers.
Inclusion/exclusion of a code in policy materials does not imply coverage.

Documentation Required

References and Documentation Expectations

No explicit prior authorization requirements are stated in the reference entries; see cited guidance documents (ACR practice parameter, ISCD positions, and relevant literature) for documentation and performance expectations that may inform medical necessity and provider documentation.

References include ACR Practice Parameter for the Performance of DXA and ISCD 2019 Official Positions — providers should use these sources to inform documentation and technical performance.
Selected peer-reviewed studies listed in references may inform clinical context but do not establish coverage.
Prior authorization: none stated in the reference entries of this section.

Definitions

Definition — DXA (Dual‑energy x‑ray absorptiometry)

TermDual-energy x-ray absorptiometry (DXA)

DefinitionUses low-dose x-rays at two energy levels to measure lean tissue mass, total and regional body fat, and bone density.

Key assumptionsEstimates are based in part on assumed constant hydration of fat-free mass (73%), and other manufacturer‑proprietary algorithms.

Measurable compartmentsDXA can estimate fat mass, lean body mass, and bone mass; regional measures (arms, legs, trunk, whole body) are possible.

Limitations notedSoft tissue measurements require areas without bone; DXA relies on assumptions that may vary across populations and disease states.

Definition — Bioelectrical impedance analysis and limitations

TermBioelectrical impedance analysis (BIA)

DefinitionEstimates body composition from electrical impedance combined with anthropomorphic data and patient factors (eg, age, sex, ethnicity).

MethodSurface electrodes on arms/feet or standing pad electrodes measure impedance; results use device‑specific proprietary regression models.

Factors affecting accuracyResults can be influenced by hydration status, fat distribution, ovulation, temperature, and device‑specific algorithms.

LimitationsManufacturer‑specific regression models are proprietary; variation arises across populations and physiologic states.

Referenced guideline — ACR DXA Practice Parameter

GuidelineACR‑SPR‑SSR Practice Parameter for the Performance of Dual‑Energy X‑ray Absorptiometry (DXA) — 2018

Role in policyReferenced as a source informing DXA performance and documentation standards.

AccessDocument available via ACR (link cited in references).

Referenced guideline — ISCD 2019 Official Positions

GuidelineInternational Society for Clinical Densitometry (ISCD) 2019 Official Positions

Role in policyCited as a source that may inform documentation and interpretation of densitometry and related measures.

Access2019 ISCD Official Positions (Adult) — PDF available via ISCD website.

References

inv-23: Reference summary — clinical contexts and citation overview

Summary of clinical contexts and citation overview (policy position on coverage noted):

Clinical context and evidence overview: Body composition measurements quantify fat, lean mass, and bone; DXA measures whole-body and regional lean tissue mass, fat, and bone density and has been used in research for assessment of undernutrition, treatment-related changes, cardiometabolic risk (visceral fat), growth and aging (including sarcopenia), and situations where BMI may be discordant with true fat mass. Systematic reviews show agreement of DXA with reference methods but studies were largely research-focused and did not demonstrate that DXA body composition measurements changed patient management or improved net health outcomes; evidence is insufficient to support clinical benefit.

Policy therefore considers DXA body composition studies investigational; outpatient use is not a covered service for listed products and inpatient procedures may require precertification as described elsewhere in the policy.

OpenPayer

DXA body composition studies

Coverage Criteria

Covered Indications

Coding

Provider Actions & Billing Guidance

Definitions

Background

Not Covered

Prior Authorization

References